ACTRN12622001200774
Recruiting
Phase 3
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Metastatic Cancer
- Sponsor
- Icon Cancer Foundation
- Enrollment
- 146
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or older
- •World Health Organisation Performance Status (WHO PS) 0\-2
- •Histological confirmation of primary malignancy (exclude seminoma, Small Cell lung Cancer (SCLC) and haematological malignancies)
- •Able to consent to trial
- •Able to safely deliver SBRT and conventional radiotherapy to all sites of disease
- •Life expectancy \>6 months
- •Able to complete QoL and pain questionnaires
- •1\-3 Lesions \<5cm in maximum dimension suitable for SBRT (excluding skull and mandible) with baseline pain score of at least 2 in target area. Lesions can be in close proximity and included in the one plan/treatment area if required.
- •Patients with spinal or intracranial metastases are eligible for inclusion but these sites will not be treated or assessed for the purpose of this trial
Exclusion Criteria
- •Patients who are candidates for curative intent or disease\-modifying treatment for oligometastatic disease
- •Patients unable or unwilling to comply with protocol requirements.
- •Pregnancy or trying to become pregnant
- •High fracture risk requiring fixation, Mirel’s score greater than or equal to 9
- •Chemotherapy or Immunotherapy within one week of radiotherapy
- •Previous radiotherapy at the treatment site(s).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
SOPRANO - Stereotactic radiotherapy alone or stereotactic radiotherapy follow by niraparib treatment for ovarian cancer with progressive disease in three or less lesions, or recurrence of 3 or less metastatic lesions that had previously achieved complete response.Oligometastatic or oligoprogressive ovarian, fallopian tube or primary peritoneal carcinomaCancerISRCTN13282459Institute of Cancer Research Clinical Trial & Statistics Unit42
Recruiting
Not Applicable
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
Recruiting
Not Applicable
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50
Completed
Phase 2
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476NL-OMON37922Vrije Universiteit Medisch Centrum20
Active, not recruiting
Phase 1
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)EUCTR2019-004952-13-BEniversity Hospital Ghent140